Semnur Pharmaceuticals Inc (SMNR) Financier

Semnur Pharmaceuticals, Inc. engages in developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California. The company went IPO on 2022-04-07. The firm's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. The company is developing SP-102 to address problems associated with corticosteroid products that are used in practice but not approved for epidural injection or the treatment of sciatica. SP-102 is a Phase III sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for use of potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is formulated without the use of preservatives and packaged in a pre-filled syringe.